The prognosis of pulmonary arterial hypertension associated with primary Sjögren's syndrome: a cohort study

Abstract

Pulmonary arterial hypertension (PAH) is a rare and severe complication of primary Sjögren's syndrome (pSS). Cohort studies indicate that the underlying diseases of PAH associated with connective tissue disease (CTD-PAH) in Asian countries are different from that in the United States and in Europe. This study investigated the clinical characteristics, survival, and prognostic factors of pSS-PAH in Chinese patients. We enrolled 29 patients with pSS-PAH who visited our referral center during August 2007 and May 2015. PAH was confirmed by right heart catheterization (RHC). Baseline demographic data, clinical manifestations, laboratory tests, autoantibody results, hemodynamics data, and treatment regimens were analyzed. All patients were followed up at the Department of Rheumatology, Peking Union Medical College Hospital (PUMCH) every three to six months. All patients were female. Mean age of pSS onset was 34.4 ± 11.1 years. Mean age of PAH diagnosed by RHC was 40.6 ± 9.0 years. There was no significant difference in age, disease duration, and hemodynamic findings between the survivors and the non-survivors in this cohort. The overall one-, three-, and five-year survival rates were 80.2%, 74.8%, and 67.4%, respectively. Prognostic factors of mortality were time between pSS onset and PAH onset (HR 1.102, 95% CI 1.017–1.185, p = 0.018) and cardiac index < 2 l/min/m² (HR 5.497, 95% CI 1.063–28.434, p = 0.042). In contrast, the use of immunosuppressants (HR 0.110, 95% CI 0.024–0.495, p = 0.004) was related to better survival. This study demonstrates that the predictors of mortality in patients with pSS-PAH include delayed onset of PAH in pSS and worse cardiac function. Immunosuppressants can improve the prognosis of pSS-PAH.

Keywords

Pulmonary arterial hypertension primary Sjögren's syndrome prognosis

Get full access to this article

View all access options for this article.

References

Chung

Liu

Parsons

et al.

Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383–1394.

Condliffe

Kiely

Peacock

et al.

Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151–157.

Ngian

Stevens

Prior

et al.

Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: A cohort study. Arthritis Res Ther 2012; 14: R213.

Hachulla

Jaïs

Cinquetti

et al.

Pulmonary arterial hypertension associated with systemic lupus erythematosus: Results from the French Pulmonary Hypertension Registry. Chest 2018; 153: 143–151.

Chung

Park

Jeon

et al.

Baseline characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci 2015; 30: 1429–1438.

Shirai

Yasuoka

Okano

Takeuchi

Satoh

Kuwana

. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: A single-centre cohort. Rheumatology (Oxford) 2012; 51: 1846–1854.

Zhao

Wang

Liu

et al.

Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. Int J Cardiol 2017; 236: 432–437.

Hao

Jiang

Zhou

et al.

Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J 2014; 44: 963–972.

Zhang

Dai

Xie

et al.

Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011; 140: 301–309.

10.

Vassiliou

Moyssakis

Boki

Moutsopoulos

. Is the heart affected in primary Sjögren's syndrome? An echocardiographic study. Clin Exp Rheumatol 2008; 26: 109–112.

11.

Kobak

Kalkan

Kirilmaz

Orman

Ercan

. Pulmonary arterial hypertension in patients with primary Sjögren's syndrome. Autoimmune Dis 2014; 2014: 710401.

12.

Launay

Hachulla

Hatron

Jaïs

Simonneau

Humbert

. Pulmonary arterial hypertension: A rare complication of primary Sjögren syndrome: Report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86: 299–315.

13.

Vitali

Bombardieri

Jonsson

et al.

Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

14.

Galiè

Humbert

Vachiery

et al.

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975.

15.

Miller

Hankinson

Brusasco

et al.

Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.

16.

Pellegrino

Viegi

Brusasco

et al.

Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948–968.

17.

Huang

Liu

et al.

Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine (Baltimore) 2016; 95: e2761.

18.

Ramos-Casals

Brito-Zerón

Seror

et al.

Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 2015; 54: 2230–2238.

19.

Chen

Yang

Liao

Huang

. Clinical features and endothelin receptor antagonist in primary Sjögren's syndrome with pulmonary arterial hypertension. Scand J Rheumatol 2006; 35: 245–247.

20.

Nakagawa

Osanai

Ide

et al.

Severe pulmonary hypertension associated with primary Sjögren's syndrome. Intern Med 2003; 42: 1248–1252.

21.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

22.

van den Hoogen

Khanna

Fransen

et al.

2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737–2747.

23.

Gunnarsson

Hetlevik

Lilleby

Molberg

. Mixed connective tissue disease. Best Pract Res Clin Rheumatol 2016; 30: 95–111.

24.

Qian

Wang

Huang

et al.

Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev 2016; 15: 250–257.

25.

Launay

Sitbon

Hachulla

et al.

Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72: 1940–1946.

26.

Phung

Strange

Chung

et al.

Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: Screening allows for earlier diagnosis. Intern Med J 2009; 39: 682–691.

27.

Humbert

Montani

Perros

Dorfmüller

Adnot

Eddahibi

. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol 2008; 49: 113–118.

28.

Sasaki

Kamataki

Sawai

. A histopathological study of pulmonary hypertension in connective tissue disease. Allergol Int 2011; 60: 411–417.

29.

Perros

Dorfmüller

Humbert

. Current insights on the pathogenesis of pulmonary arterial hypertension. Semin Respir Crit Care Med 2005; 26: 355–364.

30.

Fayyaz

Kurien

Scofield

. Autoantibodies in Sjögren's syndrome. Rheum Dis Clin North Am 2016; 42: 419–434.

31.

Kyriakidis

Kapsogeorgou

Tzioufas

. A comprehensive review of autoantibodies in primary Sjogren's syndrome: Clinical phenotypes and regulatory mechanisms. J Autoimmun 2014; 51: 67–74.

32.

Fauchais

Martel

Gondran

et al.

Immunological profile in primary Sjögren syndrome: Clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 2010; 9: 595–599.

33.

García-Carrasco

Ramos-Casals

Rosas

et al.

Primary Sjögren syndrome: Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002; 81: 270–280.

34.

Qian

Zhao

Wang

Tian

Zeng

. The role of anti-U1 RNP positivity in predicting survival in patients with connective tissue disease-associated pulmonary arterial hypertension: Angel or demon? Comment on the article by Sobanski et al. Arthritis Rheumatol 2016; 68: 1788–1789.

35.

Sobanski

Giovannelli

Lynch

et al.

Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 2016; 68: 484–493.

36.

Miyamichi-Yamamoto

Fukumoto

Sugimura

et al.

Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 2011; 75: 2668–2674.

37.

Sanchez

Sitbon

Jaïs

Simonneau

Humbert

. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182–189.

38.

Jaïs

Launay

Yaici

et al.

Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521–531.